139 related articles for article (PubMed ID: 30035186)
1. The therapeutic properties of resminostat for hepatocellular carcinoma.
Zhao J; Gray SG; Wabitsch M; Greene CM; Lawless MW
Oncoscience; 2018 May; 5(5-6):196-208. PubMed ID: 30035186
[TBL] [Abstract][Full Text] [Related]
2. Activation of mPTP-dependent mitochondrial apoptosis pathway by a novel pan HDAC inhibitor resminostat in hepatocellular carcinoma cells.
Fu M; Shi W; Li Z; Liu H
Biochem Biophys Res Commun; 2016 Sep; 477(4):527-533. PubMed ID: 27144317
[TBL] [Abstract][Full Text] [Related]
3. Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.
Bitzer M; Horger M; Giannini EG; Ganten TM; Wörns MA; Siveke JT; Dollinger MM; Gerken G; Scheulen ME; Wege H; Zagonel V; Cillo U; Trevisani F; Santoro A; Montesarchio V; Malek NP; Holzapfel J; Herz T; Ammendola AS; Pegoraro S; Hauns B; Mais A; Lauer UM; Henning SW; Hentsch B
J Hepatol; 2016 Aug; 65(2):280-8. PubMed ID: 26952006
[TBL] [Abstract][Full Text] [Related]
4. Resminostat induces changes in epithelial plasticity of hepatocellular carcinoma cells and sensitizes them to sorafenib-induced apoptosis.
Soukupova J; Bertran E; Peñuelas-Haro I; Urdiroz-Urricelqui U; Borgman M; Kohlhof H; Fabregat I
Oncotarget; 2017 Dec; 8(66):110367-110379. PubMed ID: 29299154
[TBL] [Abstract][Full Text] [Related]
5. mTOR inhibition sensitizes human hepatocellular carcinoma cells to resminostat.
Peng X; Zhang D; Li Z; Fu M; Liu H
Biochem Biophys Res Commun; 2016 Sep; 477(4):556-562. PubMed ID: 27311860
[TBL] [Abstract][Full Text] [Related]
6. Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma.
Ruf B; Berchtold S; Venturelli S; Burkard M; Smirnow I; Prenzel T; Henning SW; Lauer UM
Mol Ther Oncolytics; 2015; 2():15019. PubMed ID: 27119111
[TBL] [Abstract][Full Text] [Related]
7. Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro.
Freese K; Seitz T; Dietrich P; Lee SML; Thasler WE; Bosserhoff A; Hellerbrand C
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31635225
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase activity mediates acquired resistance towards structurally diverse HSP90 inhibitors.
Chai RC; Vieusseux JL; Lang BJ; Nguyen CH; Kouspou MM; Britt KL; Price JT
Mol Oncol; 2017 May; 11(5):567-583. PubMed ID: 28306192
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors in hepatocellular carcinoma: A therapeutic perspective.
Tsilimigras DI; Ntanasis-Stathopoulos I; Moris D; Spartalis E; Pawlik TM
Surg Oncol; 2018 Dec; 27(4):611-618. PubMed ID: 30449480
[TBL] [Abstract][Full Text] [Related]
10. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells.
Mandl-Weber S; Meinel FG; Jankowsky R; Oduncu F; Schmidmaier R; Baumann P
Br J Haematol; 2010 May; 149(4):518-28. PubMed ID: 20201941
[TBL] [Abstract][Full Text] [Related]
11. Unmasking the pathological and therapeutic potential of histone deacetylases for liver cancer.
Zhao J; Gray SG; Greene CM; Lawless MW
Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):247-256. PubMed ID: 30791763
[TBL] [Abstract][Full Text] [Related]
12. 17-Allylamino-17-demethoxygeldanamycin and ritonavir inhibit renal cancer growth by inhibiting the expression of heat shock factor-1.
Sato A; Asano T; Ito K; Asano T
Int J Oncol; 2012 Jul; 41(1):46-52. PubMed ID: 22470109
[TBL] [Abstract][Full Text] [Related]
13. Effect of the histone deacetylase inhibitor resminostat on head and neck squamous cell carcinoma cell lines.
Enzenhofer E; Kadletz L; Stanisz I; Kotowski U; Seemann R; Schmid R; Thurnher D; Heiduschka G
Head Neck; 2017 May; 39(5):900-907. PubMed ID: 28170128
[TBL] [Abstract][Full Text] [Related]
14. P53-dependent radiosensitizing effects of Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin on human oral squamous cell carcinoma cell lines.
Shintani S; Zhang T; Aslam A; Sebastian K; Yoshimura T; Hamakawa H
Int J Oncol; 2006 Nov; 29(5):1111-7. PubMed ID: 17016641
[TBL] [Abstract][Full Text] [Related]
15. The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.
Georgakis GV; Li Y; Rassidakis GZ; Medeiros LJ; Younes A
Exp Hematol; 2006 Dec; 34(12):1670-9. PubMed ID: 17157164
[TBL] [Abstract][Full Text] [Related]
16.
Liu TP; Hong YH; Yang PM
Oncotarget; 2017 Oct; 8(49):86168-86180. PubMed ID: 29156785
[TBL] [Abstract][Full Text] [Related]
17. The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal squamous cell carcinoma cell lines via the Akt/XIAP pathway.
Ui T; Morishima K; Saito S; Sakuma Y; Fujii H; Hosoya Y; Ishikawa S; Aburatani H; Fukayama M; Niki T; Yasuda Y
Oncol Rep; 2014 Feb; 31(2):619-24. PubMed ID: 24317439
[TBL] [Abstract][Full Text] [Related]
18. Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma.
Augello G; Emma MR; Cusimano A; Azzolina A; Mongiovì S; Puleio R; Cassata G; Gulino A; Belmonte B; Gramignoli R; Strom SC; McCubrey JA; Montalto G; Cervello M
Int J Cancer; 2019 May; 144(10):2613-2624. PubMed ID: 30488605
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma.
Venturelli S; Armeanu S; Pathil A; Hsieh CJ; Weiss TS; Vonthein R; Wehrmann M; Gregor M; Lauer UM; Bitzer M
Cancer; 2007 May; 109(10):2132-41. PubMed ID: 17407132
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
Ohba S; Hirose Y; Yoshida K; Yazaki T; Kawase T
J Neurosurg; 2010 Jan; 112(1):33-42. PubMed ID: 19408974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]